170 related articles for article (PubMed ID: 11094920)
1. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population.
Smith HS; Barton AE
Am J Hosp Palliat Care; 2000; 17(1):50-8. PubMed ID: 11094920
[TBL] [Abstract][Full Text] [Related]
2. Update on tizanidine for muscle spasticity and emerging indications.
Malanga G; Reiter RD; Garay E
Expert Opin Pharmacother; 2008 Aug; 9(12):2209-15. PubMed ID: 18671474
[TBL] [Abstract][Full Text] [Related]
3. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke.
Gelber DA; Good DC; Dromerick A; Sergay S; Richardson M
Stroke; 2001 Aug; 32(8):1841-6. PubMed ID: 11486114
[TBL] [Abstract][Full Text] [Related]
4. Comparative profile of tizanidine in the management of spasticity.
Lataste X; Emre M; Davis C; Groves L
Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
[TBL] [Abstract][Full Text] [Related]
5. Development of a simple spasticity quantification method: effects of tizanidine on spasticity in patients with sequelae of cerebrovascular disease.
Ogawa N; Asanuma M; Hirata H; Ota Z; Yamawaki Y; Yamamoto M
J Int Med Res; 1992 Feb; 20(1):78-86. PubMed ID: 1568522
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
[TBL] [Abstract][Full Text] [Related]
8. Role of tizanidine in the treatment of spasticity.
Neurology; 1994 Nov; 44(11 Suppl 9):S1-80. PubMed ID: 7970005
[No Abstract] [Full Text] [Related]
9. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
Medici M; Pebet M; Ciblis D
Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
[TBL] [Abstract][Full Text] [Related]
10. Tizanidine for spasticity.
Med Lett Drugs Ther; 1997 Jul; 39(1004):62-3. PubMed ID: 9217694
[No Abstract] [Full Text] [Related]
11. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
Wagstaff AJ; Bryson HM
Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
[TBL] [Abstract][Full Text] [Related]
12. [The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy].
Vásquez-Briceño A; Arellano-Saldaña ME; León-Hernández SR; Morales-Osorio MG
Rev Neurol; 2006 Aug 1-15; 43(3):132-6. PubMed ID: 16871477
[TBL] [Abstract][Full Text] [Related]
13. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C; Muff S; Smolenski-Kautz S
Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
[TBL] [Abstract][Full Text] [Related]
14. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Nance PW; Bugaresti J; Shellenberger K; Sheremata W; Martinez-Arizala A
Neurology; 1994 Nov; 44(11 Suppl 9):S44-51; discussion S51-2. PubMed ID: 7970010
[TBL] [Abstract][Full Text] [Related]
16. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
17. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Kamen L; Henney HR; Runyan JD
Curr Med Res Opin; 2008 Feb; 24(2):425-39. PubMed ID: 18167175
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological management of spasticity.
Saulino M; Jacobs BW
J Neurosci Nurs; 2006 Dec; 38(6):456-9. PubMed ID: 17233517
[TBL] [Abstract][Full Text] [Related]
19. Spasticity: a review.
Young RR
Neurology; 1994 Nov; 44(11 Suppl 9):S12-20. PubMed ID: 7970006
[TBL] [Abstract][Full Text] [Related]
20. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]